Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | AXL | P30530 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31198184 | 0.81 | HPGD (0.72) | HPGDNPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL27652929 | 0.81 | HPGD (0.76) | HPGDNPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL7715873 | 0.80 | HPGD (0.70) | HPGDNPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL15070509 | 0.80 | HPGD (0.70) | HPGDNPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL16692729 | 0.80 | HPGD (0.70) | HPGDNPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL6623847 | 0.80 | HPGD (1.00) | HPGDNPC1RAB9AKCNK3KCNK9 | |
| Hydrochloric Acid SCHEMBL27518063 | 0.79 | HPGD (0.68) | HPGDNPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL18010168 | 0.76 | HPGD (0.64) | HPGDNPC1RAB9AKCNK3KCNK9 | |
| SCHEMBL21114821 | 0.76 | PTPN1 (0.67) | NPC1RAB9AKCNK3KCNK9KMT2A | |
| SCHEMBL19921028 | 0.73 | RAB9A (0.76) | HPGDNPC1RAB9AKMT2ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3290514-B1 | APPLICATION OF PI4KIII.ALPHA PROTEIN AND RELATED MEMBRANE PROTEIN COMPLEX IN TREATING ALZHEIMER'S DISEASE | JIANGSU NUO BETA PHARMACEUTICAL TECH CO LTD (CN) | 2025-02-26 | — | — | EP | disclosed |
| US-20240173287-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2024-05-30 | — | — | US | disclosed |
| US-11766420-B2 | Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's disease | Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd. (CN) | 2023-09-26 | — | — | US | disclosed |
| US-11236378-B2 | Method for screening drug and therapeutic targets used for treating Alzheimer's disease | Jiangsu Nuo-Beta Pharmaceutical Technology Co. Ltd. (CN) | 2022-02-01 | — | — | US | disclosed |
| US-20190314321-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20190211371-A1 | Method For Screening Drug And Therapeutic Targets Used For Treating Alzheimer's Disease | JIANGSU NUO-BETA PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314321-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | PI4K2A, PI4K2B, PIP4K2A | HPGD 4795/4885NPC1 3065/4885RAB9A 491/4885 |
| US-11236378-B2 | Method for screening drug and therapeutic targets used for treating Alzheimer's disease | PSD, TBRG4, ACTR3 | HPGD 4699/4885NPC1 1606/4885RAB9A 478/4885 |
| US-11766420-B2 | Application of PI4KIIIA protein and related membrane protein complex in treating alzheimer's disease | PI4K2A, PI4K2B, PIP4K2A | HPGD 4795/4885NPC1 3065/4885RAB9A 491/4885 |
| US-20240173287-A1 | Application Of PI4KIIIA Protein And Related Membrane Protein Complex In Treating Alzheimer's Disease | PI4K2A, PI4K2B, PIP4K2A | HPGD 4795/4885NPC1 3065/4885RAB9A 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.